A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
(2019)
Journal Article
Robertson, J. F. R., Jiang, Z., Di Leo, A., Ohno, S., Pritchard, K. I., Ellis, M., …Campbell, C. (2019). A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 26(6), 703-711. https://doi.org/10.1007/s12282-019-00973-4
Background
Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC).
Methods
Meta-analysis of randomized controlled...
Read More about A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.